Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020071551 - PROPHYLACTIC OR THERAPEUTIC DRUG FOR BENIGN TUMOR

Publication Number WO/2020/071551
Publication Date 09.04.2020
International Application No. PCT/JP2019/039383
International Filing Date 04.10.2019
IPC
A61K 38/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 39/39 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/82 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
82Translation products from oncogenes
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
CPC
A61K 38/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/82
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
82Translation products from oncogenes
C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;
10Cells modified by introduction of foreign genetic material ; Not used, see subgroups
Applicants
  • 株式会社癌免疫研究所 INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. [JP]/[JP]
  • 大日本住友製薬株式会社 SUMITOMO DAINIPPON PHARMA CO., LTD. [JP]/[JP]
Inventors
  • 杉山 治夫 SUGIYAMA Haruo
Agents
  • 山本 秀策 YAMAMOTO Shusaku
  • 森下 夏樹 MORISHITA Natsuki
  • ▲駒▼谷 剛志 KOMATANI Takeshi
  • 飯田 貴敏 IIDA Takatoshi
  • 石川 大輔 ISHIKAWA Daisuke
  • 山本 健策 YAMAMOTO Kensaku
Priority Data
2018-19046105.10.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) PROPHYLACTIC OR THERAPEUTIC DRUG FOR BENIGN TUMOR
(FR) MÉDICAMENT PROPHYLACTIQUE OU THÉRAPEUTIQUE CONTRE UNE TUMEUR MALIGNE
(JA) 良性腫瘍の予防または治療薬
Abstract
(EN)
The present disclosure provides a prophylactic or therapeutic drug for benign tumor. Provided is a prophylactic or therapeutic drug for benign tumor that comprises a WT1 peptide, an analog thereof, or a nucleic acid molecule encoding the same. In a specific embodiment, the present disclosure provides a prophylactic or therapeutic drug for benign tumor that comprises a WT1 peptide, an analog thereof, or a nucleic acid molecule encoding the same. In a preferred embodiment, the prophylactic or therapeutic drug according to the present disclosure for benign tumor (for example, familial adenomatous polyposis) comprises killer type and/or helper type WT1 peptides. In a further preferred embodiment, the aforesaid WT1 peptide is WT1126 killer peptide and/or WT135 helper peptide. In another aspect, provided are WT1 peptide-specific CTLs, a method for inducing WT1-specific helper T cells and a method for inducing dendritic cells presenting a WT1 peptide.
(FR)
La présente invention concerne un médicament prophylactique ou thérapeutique contre une tumeur bénigne. L'invention concerne un médicament prophylactique ou thérapeutique contre une tumeur bénigne qui comprend un peptide WT1, un analogue correspondant ou une molécule d'acide nucléique codant pour celui-ci. Dans un mode de réalisation spécifique, la présente invention concerne un médicament prophylactique ou thérapeutique contre une tumeur bénigne qui comprend un peptide WT1, un analogue correspondant ou une molécule d'acide nucléique codant pour celui-ci. Dans un mode de réalisation préféré, le médicament prophylactique ou thérapeutique selon la présente invention contre une tumeur bénigne (par exemple, une polypose adénomateuse familiale) comprend des peptides WT1 de type tueur et/ou de type auxiliaire. Dans un autre mode de réalisation préféré, le peptide WT1 susmentionné est le peptide tueur WT1126 et/ou le peptide auxiliaire WT135. Dans un autre aspect, l'invention concerne des LTC spécifiques à un peptide WT1, un procédé pour induire des lymphocytes T auxiliaires spécifiques à WT1 et un procédé pour induire des cellules dendritiques présentant un peptide WT1.
(JA)
本開示は、良性腫瘍の予防または治療薬を提供する。WT1ペプチドまたはその類縁体、あるいはこれをコードする核酸分子を含む、良性腫瘍の予防または治療薬が提供される。特定の実施形態では、本開示は、WT1ペプチドまたはその類縁体、あるいはこれをコードする核酸分子を含む、良性腫瘍の予防または治療薬が提供する。好ましい実施形態では、本開示の良性腫瘍(例えば、家族性大腸腺腫症)の予防または治療薬は、キラー型および/またはヘルパー型のWT1ペプチドを含む。さらに好ましい実施形態では、上記WT1ペプチドは、WT1126キラーペプチドおよび/またはWT135ヘルパーペプチドである。別の局面において、WT1ペプチドに特異的なCTLs、およびWT1特異的ヘルパーT細胞の誘導方法、ならびにWT1ペプチドを提示する樹状細胞の誘導方法が提供される。
Latest bibliographic data on file with the International Bureau